AI converges with aging biology: Ronjon Nag's path from speech to immune design

Ronjon Nag, founder of Agemica, has been appointed Officer of the Order of the British Empire for services to entrepreneurship and artificial intelligence—a recognition that mirrors a deeper shift in longevity biotech: AI is no longer a peripheral tool but part of the foundational infrastructure by which aging biology is being mapped, modeled, and therapeutically interrogated. His platform applies proprietary AI systems with an mRNA-based architecture to identify shared molecular targets linking cancer, neurodegenerative, cardiovascular, and metabolic disorders, circumventing the traditional silo approach of targeting diseases in isolation. Ex vivo studies demonstrated tumor reduction across 13 cancer types using AI-designed peptides, and several proprietary drug combinations produced synergistic effects across multiple cancer models. Though work remains preclinical and requires validation in humanized mouse models—with pancreatic cancer as an initial target—the significance lies not in any single platform but in disciplinary convergence: AI researchers becoming drug developers, computational scientists entering geroscience, and historically separate fields developing porous boundaries. For the longevity-curious reader, this signals transition from eccentric future-gazing toward genuine clinical and economic consequence.